<a href="https://www.fiercebiotech.com/biotech/astrazeneca-plucks-egfr-degrader-pinetree-25-million" hreflang="en">AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M</a>
fiercebiotech.com·Apr 30, 2026
AstraZeneca has acquired a preclinical EGFR degrader from Pinetree Therapeutics for $25 million, following a previous agreement worth $45 million. This collaboration aims to develop a therapy targeting EGFR-expressing tumors, leveraging Pinetree's AbReptor platform to potentially address drug resistance in oncology.
AstraZeneca's $25 million licensing of Pinetree's preclinical EGFR degrader highlights the potential of protein degradation platforms in addressing drug resistance in oncology. This deal emphasizes the growing interest in targeted therapies for EGFR-expressing tumors, signaling a lucrative opportunity for investment in companies developing similar precision medicine technologies.